VERU

VERU INC. (VERU) - 10-K Summary

Business Context and Reporting Period

Company: VERU INC.
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2025
Business Overview: Veru is a late clinical-stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases. Following the sale of its FC2 Female Condom business on December 30, 2024, the company has no commercial revenue and is solely focused on developing two drug candidates: enobosarm (for obesity/muscle preservation) and sabizabulin (for atherosclerosis inflammation). The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: The company reported a gain on the sale of ENTADFI assets of $10.8 million and a gain on extinguishment of debt of $8.6 million in Fiscal 2025.

Material Changes vs. Prior Period

• Discontinued Operations: The FC2 business was sold on December 30, 2024. This resulted in a $4.1 million loss on sale and the reclassification of all FC2 revenues and expenses to discontinued operations. Consequently, the company currently has no commercial revenue.
• Operating Expenses: R&D expenses increased by $2.8 million (22%) due to the Phase 2b QUALITY clinical study for enobosarm. SG&A expenses decreased by $4.7 million (19%) primarily due to reduced share-based compensation.
• Asset Sales: The company settled the sale of ENTADFI assets with Onconetix, Inc. (ONCO), receiving $6.3 million in cash and equity securities, recognizing a $10.8 million gain.
• Debt Extinguishment: The Residual Royalty Agreement was terminated upon the FC2 sale, resulting in an $8.6 million gain on extinguishment of debt.
• Reverse Stock Split: A 1-for-10 reverse stock split was effected on August 8, 2025, to maintain Nasdaq listing compliance.

Guidance, Outlook, and Risks

Going Concern: The independent auditor has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern for twelve months following the report date. Management estimates current cash is insufficient to fund operations for the next 12 months without additional financing.

Clinical Outlook:

• Enobosarm: Positive Phase 2b QUALITY results showed 100% relative reduction in lean mass loss when combined with semaglutide. A Phase 2b PLATEAU study is planned to begin in Q1 2026 to evaluate incremental weight loss.
• Sabizabulin: Development is being explored for atherosclerosis inflammation. A Phase 2 dose-finding study is planned pending funding.

Key Risks:

• Liquidity: Need for substantial capital to fund drug development; failure to raise capital could force cessation of operations.
• Regulatory: Risks associated with FDA approval, clinical trial delays, and potential government shutdowns affecting FDA review times.
• Legal: Ongoing shareholder class actions regarding prior statements on sabizabulin and a lawsuit filed by the purchaser of the FC2 business (Clear Future, Inc.) alleging breach of representations.
• Internal Controls: While previously identified material weaknesses in internal controls were remediated, the company faces risks of future deficiencies.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $15.8 million cash balance against the projected burn rate for the upcoming Phase 2b PLATEAU trial and general operations.
• Financing Plans: Review the status of the October 31, 2025 equity offering (net proceeds ~$23.4 million) and any other pending capital raises to mitigate the going concern risk.
• Legal Exposure: Assess the potential financial impact of the Clear Future lawsuit regarding the FC2 sale and the ongoing shareholder class actions.
• Clinical Milestones: Monitor the start date and enrollment progress of the Phase 2b PLATEAU study scheduled for Q1 2026.
• Supplier Obligations: Confirm the status of the $2.4 million remaining liability to a supplier regarding the sabizabulin dispute resolution.